HAE HAEMONETICS CORP/MASS
2026Q1 · CUSIP 405024100 · Sector: Healthcare & Biotech
Danger · Dual-confirm: breadth + price
Holders
321
Δ holders QoQ
-8
Breadth percentile
Top 83%
Whale holders
165
Δ whales
+1
Inst. holding value
$2.6B
New positions
55
Closed positions
63
Price momentum (1Q)
-2.2%
Put / Call
5/3
Breadth history (34 quarters)
Past Lit Events & Aftermath 7 lit events
| Period | Percentile | Next-1Q return | Next-2Q return |
|---|---|---|---|
| 2025Q4 | Top 18% | -2.2% | — |
| 2024Q2 | Top 10% | +20.5% | -15.5% |
| 2022Q4 | Top 15% | +2.4% | +4.3% |
| 2022Q3 | Top 3% | +1.9% | +5.5% |
| 2019Q3 | Top 9% | +0.3% | -10.7% |
| 2018Q2 | Top 5% | +2.9% | -15.0% |
| 2018Q1 | Top 13% | +15.4% | +18.7% |
Options Sentiment
Put holders
5
QoQ: -2
Call holders
3
QoQ: -8
See methodology →
Fundamentals
PE (TTM)
38.0
EPS (TTM)
$2.05
EPS YoY
-38.1%
Revenue (TTM)
$1.3B
Revenue YoY
-2.0%
Net margin
7.3%
ROE
12.2%
Debt ratio
66.8%
FCF (TTM)
$260M
Dividend (TTM)
No dividend
Quarterly Revenue & EPS (4Y)
Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable
P/E (TTM) over time
P/E = close 47 days after quarter-end (filing date) ÷ TTM EPS then; loss quarters hidden
As of 2026-03-28 · SEC filings (XBRL)
Get the next update
2026Q2 holdings publish around Aug 15 — subscribe to receive the lists first.